All right, guys, we're gonna get going here, and I just mentioned earlier we're making the move from animal health to dental. And next up, we have Dentsply Sirona, one of the leaders in the dental market, and joining us is Glenn Coleman, Chief Financial Officer. A little bit of a different approach. I, you know, dental's had some, I guess, headwinds, more specific to the stocks necessarily, and, you know, I'd speak to a lot of investors and there's some concerns out there. So I came up with a question that I'm asking. Yep Most of the dental companies participating in the conference, and I'll run it by you, Glenn, and would love your answer to it. Look, dental stocks have underperformed since emerging from COVID. I've got investors that say, "Hey, there's value in implants, there's private label, there's pricing power that is more subdued relative to other industries." They sort of question the structure of the market, just from an investment perspective and, you know, I'd love to get your thoughts on those concerns, just high level, and then maybe we'll get into how your portfolio can help address some of those issues. Yeah, no, I think not so much a concern, but just some of the trending of moving from premium to value brand is clearly taking place in the market. I think Dentsply Sirona is well positioned across the portfolio. So if I think about implants as an example, we have a good premium offering called OmniTaper, and it has multiple different implant systems. We've got a value offering as well, called Make It Simple, and so we've got premium and value. If you look at other parts of the portfolio, though, even in CAD/CAM as an example, we have a lower price scanner that we rolled out about a year ago, called Primescan Connect. So that hits a sweet spot in the overall market. More recently, in imaging, we rolled out Orthophos, which is a lower-priced imaging alternative, both 2D and 3D, as an example. Even in certain other categories, like restorative, in endo, we have value or fighter brands. So as some of the market shifts to focusing on cost, which is a big issue for our customers, clearly we have alternatives that we can offer across our portfolio. Okay, very helpful. And, do you think the customers being more cost-conscious is that picked up of late? Is that a function of inflationary pressures? Do you think incrementally there's more focus coming from your customer base relative to years past? Yeah, I would say certainly the last three or four quarters, we've seen through our surveys, and we do several thousand responses in each of our quarterly surveys from our customers, telling us that cost is a number one issue in their businesses and their practices. Obviously, staffing shortages are also an issue, but cost being an issue, clearly they're looking for alternatives. You know, it's not just about the cost of the product, but how can you get economics better for their practice? So I don't just focus on: Here's what it costs for our products, but how can we improve, you know, patient flow through their practices? How can we get them better economics? A lot of this is all through digital dentistry and our offering, but clearly, they're focusing on cost. Yep. Part of it is the cost of the product, part of it is: How can I be more efficient in my practice? How can you, Dentsply Sirona, help me, you know, improve the economics of my practice by improving my patient flow? You feel like you've got that diverse portfolio to go ahead and do that? Absolutely. Okay. Yeah. I'm gonna go through product lines, I'll hit on some geographies, I'll zoom out and go to margins, and we'll go from there. So I'll start with CTS, and you know, that's been probably the most difficult division for the company, most of the pressure emanating from imaging. You just brought it up. I think on the last call, you talked about company-specific initiatives, right? Orthophos SL being introduced- Mm-hmm, mm-hmm. Some promotions. Are you seeing those actions take hold in the marketplace, or is that something like: Hey, John, this is a little bit more longer term that needs to play out over time? Yeah, so when we talk about CTS, it's our Connected Technology Solutions offering. It's obviously heavily equipment based, so think of it as CAD/CAM equipment, everything from intraoral scanners, to mills, to 3D printing, along with other equipment, imaging equipment, instruments. So that kind of makes up what we call CTS, along with our DS Core software platform. We've actually done well in CAD/CAM. So if you think about the intraoral scanners, mills, printers, that's actually held up pretty well in this tough macro environment. Where we have struggled is on the imaging side, and this is typically equipment that's priced at much higher price points. Almost always gets financed, and obviously, with higher interest rates, it puts a lot of pressure on customers moving forward with financing at 7%-8%, versus previously at 3%-4%. So you know, we've seen a lot of pressure there. It's not just the macro for us, though. We have lost some market share on the imaging side, and to your point, we've now relaunched this lower priced alternative called Orthophos in the European market. So we think that's gonna help, but certainly, we expect kind of the imaging area to be under pressure for the remaining part of this year. You know, and just to put it into perspective, last couple of quarters, we've been declining 30% in imaging, right? So it's been pretty substantial. I think we expect to see declines in the back half of the year, but not to that extent. So we do expect to see some improvement with the relaunch of Orthophos, with some of the initiatives that we're rolling out, but clearly, that's been the headwind in our overall CTS business. And with that, you know, in the Q1, we posted a decline of about 5% organically. Mm-hmm. And so, obviously, it's been a big headwind when you look at our overall performance. Okay. You know, as you mentioned, CAD/CAMs held up better. Let's go to CAD/CAM. There's a lot going on in there. I mean, you've got Primescan, you've got CEREC Primemill, you've got Primeprint. Can you deconstruct, you know, how those, how those products are faring? And how is the mill holding up in light of 3D printing and any potential cannibalization that you're seeing there? You know, it's a great question. I think, you know, we've been very focused on intraoral scanning. It's kind of the, the lead-in to everything that's digital dentistry, so we've been very focused on both our standalone offering, which is Primescan Connect, along with our full chairside offering, which is Primescan AC. We've seen some very good traction there. I think we've rolled out a number of promotions in certain markets outside the U.S. and seen some good pickup there. So favorable reimbursement that's taking place in certain markets, like Japan as an example, where they're gonna get now reimbursed for, for scans, and we think that that's an opportunity for us as we go forward here. So on the whole, I would say we're doing well in scanners. Big focus for us, will continue to be a big focus for us. On the milling side, you know, I think in this tough macro environment, it's a good question to say, "Well, why is milling actually doing so well?" And I think there's a real good value proposition for customers, where if you can design and do your own mill in-office through single-office dentistry, there's a huge return on investment, right? And a very fast return on investment. And so that's kinda how we, we really play into this milling space. We're obviously the leader in the category. And then 3D printing, obviously, is still a small part of our business. Seeing a nice uptake. We've obviously rolled out some new resins, especially around the splint area. But we see clearly a nice runway ahead on 3D printing. But, you know, there's a lot of buzz out there around, "Is 3D printing gonna replace milling?" We clearly see them as complementary, and not in conflict with each other, and not in a cannibalization situation. If you think about milling, obviously, the durability of a crown, the strength of the crown is very different when you mill versus when you print, so we view it as permanent versus temporary when you talk about milling versus printing. The aesthetics are very different. Much better when you look at a milled crown versus a printed crown, and just time to actually mill versus print is different. And so there are advantages to milling. There's cosmetics that are better today. Down the road, could that possibly change? Of course, and I think we're looking at things within our own R&D area to figure out how we can advance the 3D printing strategy long term. But today, in the short term, intermediate term, we see them as very complementary. And maybe to that end, Glenn, are you seeing some of those early Primeprints going into mill practices? You know, are they just sort of tech-savvy leaders, and so sometimes you're actually placing a Primeprint alongside a PrimeMill? Yeah, I, I think clearly where we have single-office dentistry, it's a sweet spot to have a 3D printer included. So we o bviously, that's kind of a first and foremost area we go after when we look at 3D printing. But that doesn't mean you have to be a, a single-office dentistry type of practice to actually have a 3D printer. So we see both, but I, I would agree with your point. That's probably the easiest opportunity and where we'd have the immediate impact is going into those types of practices. Okay, and then maybe one more down the CTS road, and we'll pivot off. But, you know, you've got DS World, I believe, in September, and then it's an IDS year in 2025. Sometimes I feel like Dentsply's trying to use this as almost as a launching pad of new products. You see it in the U.S., and then, you know, four, five, six months later, you're almost able to roll it out to the international markets. Should we be more attentive to what that might mean from a product cycle standpoint going into DS World this year, considering IDS is shortly behind it? Yeah, I think the way Simon Campion, our CEO, thinks about product launches is we're not gonna wait for a DS World event to launch a product, right? We're gonna launch the product when we are ready, and I think you will see some new innovation coming out as part of the DS World Las Vegas show that's gonna be happening here in September. But we are pretty excited about some things that are coming out. It's gonna be in the digital dentistry space. I'll just leave it at that at a high level, don't wanna spoil the fun yet. But we do have some innovative products that are gonna be launched here, I would say, in the second half of this year, and they will be showcased at our DS World events coming up. Okay, and, you know, maybe just again, one last one on CTS. It's hard to see a path towards 4% growth next year in 2025 without the resumption of growth in CTS, right? I mean, you're doing so well in ortho- Mm Y ou're really getting some momentum in implants. EDS has tight error bands around it for the most part. So when you take it back to CTS to get to that 4% bogey, that's my term, do you feel comfortable in the resumption of growth? You mentioned earlier, imaging down 30%, but the decline slowing. Yep. CAD/CAM has done well. Seems like there might be a fit of a new product in the segment. Can we think about growth in 2025 CTS? Yeah, listen, I think the biggest wildcard and risk we have is CTS returning to growth. So you hit all the points. We're doing well in most parts of our portfolio, growing nicely. Clearly, when you think about CTS, I don't think you should look at it as a broad category. I think we'll continue to do well in CAD/CAM. The area of imaging and getting that back to even neutral would be a huge benefit to us, and obviously, the relaunch of Orthophos should help. You know, hopefully, we'll see some better macroeconomic conditions in certain markets like Germany, and we call Germany out because it is, you know, our second-largest market behind the US. It's 10% of our consolidated sales, but Germany is a heavy-focused equipment market for us. So you look at CTS, it's probably about 30% of our total sales when you look at CTS to total, total Dentsply Sirona. Germany is two times that. Mm. Right? And so Germany is heavily equipment dependent, and so Germany returning to better performance is gonna be a key around this, especially imaging. But our goal is to try to get imaging to kind of at least get to be down low single digits or even flat. I think CAD/CAM will grow. And if we could do that, to your point, the rest of the portfolio is actually doing pretty well, and that will be the key to us getting to 4% or 5% in the outer years of our long-term plan. But it's clearly the biggest risk and wild card right now. And if I could follow up on Germany, it's funny, I was gonna go through all your product, but I'll fast-forward to Germany and then take it back. As you mentioned, biggest market outside the U.S., you alluded to weakness on the 1Q call. I think you said it's down 15% year-over-year in 1Q 2024, double-digit declines for the past four quarters, and you expect a double-digit decline in 2Q 2024. That said, you do all this great survey work. Your proprietary survey, I think, got less bad- Yeah in 1Q 2024. We do what we can in Germany. Tough, but when we roll up our sleeves and we're looking at consumer confidence, it's not great, but it's actually improved off the lows for the past four months and had a decent reading this morning. Are you seeing any early signs of, like, thawing or second derivative that we can attribute to, to Germany? Yeah, no, listen, I think we rely heavily on our survey results, and even if you just look at Germany standalone, we had over 200 responses in the survey that we just did in April, and it was less bad than previous surveys, to your point. Yeah. So, it looks like things are hopefully now moving in a better direction, but it is still a challenging market for sure. Customers still have concerns around the cost in their practices. Patient traffic is still sluggish. It's the highest concern in terms of staffing shortages versus all the markets that we survey. So it's still a challenging situation, but I think on the whole, you know, we are starting to see some silver linings, but we're not gonna start calling a turnaround until we actually see the results. And I do think that this Orthophos relaunch should help us as well. This was a product that was very successful in Germany before it was discontinued several years ago. And so, I'm pretty encouraged by some of the early signs and what we're seeing there in the first two months of launch there. But, by no means are we expecting growth in Germany this year. I just think having a lower level of decline in the back half of the year would be an improvement from where we're currently at, 'cause you mentioned we're declining 15% plus in Q1, probably the same thing in Q2, and so getting that back to a single-digit decliner would be an improvement from where we are today. Big weight on the overall top line when you try to tie it back to growing 4%. Okay, and then I'll take you back to the divisions, and EDS was down mid-single digits in the first quarter. There was a really difficult comp from a year ago. But you've talked about low single-digit growth in the back part of the year, I think to get around flattish for full year 2024, and the 4Q comp's not easy. So I've gotten questions like, "Hey, what drives that acceleration and growth in 2H when we think about EDS? Yeah, so just to put into context, you know, we were down in the first quarter, but last year's first quarter in 2023, we had close to 12% growth, so the comp was extremely difficult. That's the reason why we were down, down kind of mid-single digits in Q1. We would expect kind of our EDS business, which is Essential Dental Solutions that consists of preventive, restorative, and endodontics, as part of that part of our business, to grow pretty consistent with patient traffic, right? And so low single-digit growth is our expectation. We also have a product that we've just launched in Europe and certain parts of Asia in the endo space called X-Smart Pro+. It's a new endo motor. Seeing some really good results early on. We're expecting to get the U.S. approvals and launch here later this year. And so that should help our overall EDS growth in the back half of the year versus, you know, the front half of the year. But a lot of it is comps. I, you know, the Q4 comp, I think last year, we grew 3%-4%. Three, yeah, Three and change. Right. So it's not the 11%-12% we saw in Q1, but clearly, we expect better performance in EDS. Comps were the big issue, but the new product launch should help as well. And just how about pricing power and consumables? You know, I, I said prior to you taking the stage, we're doing animal health, right? And animal health has really had a lack of volume growth, but you see consistent price of Three, Four, maybe even in some cases, 5%. Obviously, that's not the case in dental, but is there this ongoing shift, you know, on a private label, on a trade down, where really that EDS long-term growth algo is just, pardon the term, but more hostage to volumes and unlikely to get any price realization? Can you talk to those dynamics? Yeah, no, I totally agree with you. I think all of the growth in EDS going forward is gonna come from volume. I think raising prices right now is the wrong thing to do. Customers will shift and continue to move towards lower-cost brands if you're gonna raise your prices, and so, you know, we were able to do that, I would say, last couple of years, with inflation being what it was. But our view going forward is pricing is kind of flat to even down slightly. And so any growth coming out of EDS is gonna have to come from volume-based. That's the way to think about it, at least as we look at the next three years. Okay. And then your ortho segment, your fastest growing division, and really across two different areas. So let's go with Byte. We'll start there. Mm-hmm. You started to see increasing traction post the SmileDirectClub bankruptcy. You're now pointing to north of 20% growth this year. The big question I get is sort of your level of confidence that success continues into 2025. I I think the pushback I get is it a one-time step up due to SDC exiting, and then you still grow- Yeah B ut, you know, it's a higher base of the level of growth that we're able to subscribe to that step up. Yeah, no, listen, I think we're really happy with the performance of our Byte business. This is a direct-to-consumer business. We are taking advantage of some of the competitive dynamics, so one of the big competitors exited the space in end of 2023, and we saw an immediate uptick in our business when that happened. We are seeing some really good, positive leading indicators for this business, so impression kit growth up significantly, and I mentioned on the earnings call, I think, +50% growth in impression kits, just as an example, that's a lead indicator. Seeing really good, unique patient traffic going through our website, really good lead indicator. We saw this coming, and we forward invested in this business. Added a number of treatment planners, clinical operations, support people, salespeople, et cetera, knowing that we're expecting to see a faster growing business as we move forward. I don't think it's a one-time bump, and then it kind of comes way down in 2025. I think we'll have to talk about what 2025 looks like when we get closer to the end of this year. Clearly, this is a business that should be growing double digits consistently. You know, we're probably seeing some additional benefit here in 2024, but in addition to the competitive dynamics, we've rolled out this Byte+ model, we call it. It's a hybrid model where you do an initial consult with a general practitioner, get the scan done. They say you're a good treatment per person for the direct-to-consumer treatment plan being from home. and so that hybrid model is now fully commercially launched, and we feel like there's gonna be some good traction around that. Should help our conversion rates. And then on top of that, we're seeing a really good uptick in accessories. So with every aligner going out now, you know, we offer things like teeth whitener, retainers, The add-ons. The add-ons, all these accessories, and we're seeing about a 40% attach rate right now, and that's increasing, which is a really good additional revenue source for the Byte business. So we're excited about that as well. So with the accessories and Byte+, even off that step-up in 2024, again, you're not gonna give us a number, obviously, but, like, a double digit- I mean, SDC's gone, Candid pivoted their business model, so I don't wanna say last main company of scale are standing in that area of DTC, but that could lead to ongoing double digit- Yeah - growth for that. No, I think that's a fair characterization. Unless we said at our Investor Day in November, the ortho business for us, which is this Byte business, I'm sure we'll talk about SureSmile in a minute, is a business we expect to grow 20%. I mean, that is a goal that we've set for ourselves. Clearly, Byte's gonna grow faster this year based upon our comments. Yep. But SureSmile, which is our in-office brand, our professional brand, if you will, is also doing really well. So to pivot to SureSmile, I was at AAO, New Orleans, and one of the things I was a little surprised about in a good way was I thought your presence was bigger, quite honestly, just like physically, your booth- Yep T he people. I always thought about, you know, if you're gonna continue to gain share with SureSmile, you're gonna do it through, call it, like, same-store sales. You've mentioned geographically- Yep you push into some new markets. What about the push into ortho? I mean, you've got such a strong foothold in GP because of Primescan, right? So that's very logical, but do we think about SureSmile as new geographies taking precedent, or are you gonna push harder into ortho in that regard? No, listen, I think, we are very focused, and we'll stay focused on the GP side, less on the ortho side for now. The main reason for that is we used to be in brackets and wires number of years ago. We exited that space, and so right now, our sweet spot is with the GPs. Doesn't mean we will always be in this space. At some point, maybe we, we do a bigger focus on the ortho side, but, you know, for us, it's geographic expansion. We are now selling SureSmile in over 50 countries. I don't think we want to go to 100. I think we're in the right countries now. We wanna go deeper, and so we've talked about incremental investments in places like Japan and in Brazil, for example, that we're doing this year. We'll expect to go deeper in those countries. We've got some really good clinical data around fewer refinements, less revisions, using SureSmile versus other products that are on the market. Yep. That means, you know, patients not coming back after the treatment plan, taking up chair time, better economics, obviously, for the practitioners. So feel really good about that. We've just also recently launched our SureSmile Simulator, hearing- Before and after. Before and after, what does it look like? Really helps to convert patients at a higher rate, and so these are all things that are moving in a positive direction. We're still a small player, though. We're still a $400 million-plus business when you think about our total ortho business, but clearly a lot of runway for us. We think we're taking market share in both spaces, both on the professional side and direct-to-consumer side, and it's a business we're very excited about and expect to grow, you know, at least in that double-digit range over the long term. So that's gonna be the fastest-growing division, obviously, and I'll move to implants, and then we can go to margins and earnings cadence and stuff like that. But on implants, it's funny, I go back to IDS of 2023, and I visited a lot of the booths and met with some of the companies, and everyone was gonna take share. Everyone was gonna gain share, and obviously, that's... I can do that math. That's not gonna happen. And so you've got new implants from Straumann in North America. You guys have talked about improving your results. You know, nothing heroic overnight, but improving your results. I think exiting 2024 with some growth and getting to market growth closer to 2026. Mm-hmm. You've made some commercial investments. You'll actually have a symposium coming up. Take us through that trajectory of improving the growth rate and then eventually market growth and how you get there. Yeah, so if you think about the big markets for us, China is a big market for us when you think about implants. We've actually done really well with VBP. We were one of the big winners last year. We've seen a really nice uptick in volumes. So even with some of the pricing reductions, we're actually growing very nicely in China. In Europe, last couple of quarters, we've been growing in-line or faster than, I'll say, the big competitor in the space. Our challenge has been the U.S. business, and these were self-inflicted wounds. We cut back on a lot of the clinical education spend several years ago. We had a significant amount of sales force turnover, where you'd have literally a new rep every year going out to these customers that are oral surgeons that are really looking for a rep to be an extension of their practice, and when you have turnover, it is very disruptive for them. And we lost market share, we lost customers. And so we've been fighting to win that back, and that's been the challenge for us, I would say, over the last 18 months. And, you know, we're doing a lot more on the clinical education front. You mentioned we've got a big symposium coming up in two weeks. Hopefully, you'll be joining us in Miami. We have over 500 customers coming to this event, half in the U.S., half outside the U.S. We did a similar size event in Athens, Greece, last year. We're doing a whole bunch of localized events. So clinical education, area of investment, that's critical in this space, and I think we've now done a lot to shore up our sales force. We've got very low turnover. I think in the implants team, in the last 12 months, our turnover has been, you know, around 5%, which is a significant improvement from where we've been at. And so now we've got to start to see the turn in our actual performance, and we haven't seen it yet. We've seen a lot of green shoots, we call them, good, positive indicators. But we have message that we do expect to see better performance in the second half of this year and returning to growth before the end of the year. And so the commercial investments, you've got greater stability there. You've got the portfolio, you know, premium and value. Yep. Is there anything else you need? I mean, is this gonna be a venue for releasing new products, or do you think from a product portfolio standpoint, implants is where it needs to be? No, listen, we just did an extensive survey around our portfolio to several thousand customers, and it came back that we have a strong implants portfolio. We came back as number one in digital dentistry. That was good to hear, and that was by a pretty wide margin versus number two and number three in the space. On implants, we were not number one, we were top three, but the differential was only a few percentage points, so statistically, not even significant, and it came back that we don't have any glaring gaps in the portfolio. So we think we have the portfolio. We have premium, we have value, we actually have bone regeneration products as well with our Ossix product line. So we feel like we got the portfolio, we've done the steps we need to take in terms of the U.S. implants business. Now, we've just got to start to show results. Okay. Very helpful. We fleshed out the product lines. We touched on Germany. I'm gonna pick your brain a little bit on 2024 cadence and maybe some 2025 moving parts. So 2024 cadence, I'll just go through it. On that revenue pickup or the acceleration in 2H, we should look for a stronger growth rate from EDS in the back part of the year, part of that's comps, implants improves, and just call it ongoing traction in ortho and Wellspect. When you roll that up, you should get a faster growth rate in 2H relative to 1H. I've gotten questions on EPS, so you mentioned- Can I just, just add one thing? Please, sorry. So just on the implants piece, I would say we're not messaging faster growth second half versus first half for implants. It's kind of more flat growth because China, we're expecting to see more moderate growth with higher, you know, more difficult comps coming, and then improved performance in Europe and U.S. kind of offsetting that, the China slowdown. So I would say implants, we're not expecting to see a sequential improvement second half versus- On a global basis, you'll have those changes within the region- Yes ... due to what you mentioned in China. Yes. Got it. That was very helpful. Thank you. Then EPS, you mentioned, too, Q 2024 EPS down slightly. You know, we can all sort of geek out with the model. I'm arriving at 45% of 2024 EPS growth derived in the first half. Yep. I have that as the lowest percentage since 2017, so obviously, EPS is back-ended. And I thought you gave a really helpful nugget on the call where you said: "Hey, look, there's gonna be $0.20 in the back part of the year." You called it, like, a third coming from the faster- Right O rganic growth, and then two-thirds from restructuring starting to hit the P. Now, that's the right way to think about it and why the 2H—we should be comfortable with 2H EPS being back-ended? That's exactly right. Okay. So yeah, obviously, we're expecting to see better top-line performance in the back half of the year, and then all the restructuring work, we're gonna start to see some of those benefits, you know, pull through. And I also mentioned, you know, we made some incremental investments here on the commercial side with, you know, our Byte business, SureSmile in Japan, Brazil. We should start to now see some of the bear fruit from those investments as well. So yeah, that's the right way to think about it, and that's how we get to the $2 on a full year basis. In the last two minutes, maybe just to go over to the 2025 moving parts. You've talked about $0.30 in total restructuring savings. Again, you know, you've got the two-thirds of $0.20. You'll see $0.13 or $0.14 roughly in the back half of 2024. Mm-hmm. The balance of that would occur in 2025 to get to, like, a $0.30 net number. Is that correct? Yeah, so we said $0.30 over the entire window. I think, the restructuring program will be complete, obviously. So clearly, you'd expect to see a bigger benefit going into 2025, but we're still looking at how much we wanna reinvest. So I don't wanna commit yet to an exact number for 2025, but clearly, the way you're laying this out is the right way to think about it. So the $0.30 might not be a net. That could be a little bit of a gross with some reinvestment going to some other area. We will get the $0.30 over the three years. My only point is, we may choose to invest and then see some additional benefit roll out in 2026. That's my only point. But we will get $0.30 of a net benefit over the three-year window from 2024 to 2026. Okay, so then with, like, one minute left, I guess I'll get to the sort of the punchline, which is just. You know, we use a $2 number this year. That's my number, right? $2, $2, and we think about your $3 goal, which you need some revenue acceleration. But how would we weight the $2-$3 between 2025 and 2026? In other words, the restructuring's all 2024, 2025, the SKU optimization and is a little 2025, 2026. Would it be a greater growth contribution, 2024 to 2025 or 2025 to 2026 or linear? And let me know if that question made sense. It made sense. I'm not sure I'm gonna answer it, though. So, you know, I think relative to 2025, we haven't laid out our guidance yet. Clearly, we're expecting to see a big benefit in 25 as well as 2026. You know, we've talked about this bridge to $3.67 being in our control. You know, some of that is ERP. That's clearly 2026. Some of it's the restructuring. Obviously, you'd expect more in 2025, but as we get closer to the end of this year and seeing where we land and have a good view of our plan for 2025, we'll give you more specifics on how the benefits are gonna roll out. But that 255-260x the growth. In other words, if growth were to even remain modest in the way that you said, you know, out of the $3.40-$3.45 is contingent on the faster growth, you feel comfortable in and around that level, even if growth were not to re-accelerate from here? Yeah, I think the things that we can control, are on track so far. So, you know, relative to the bridge, that $0.40-$0.45 bucket, let's just set that aside- Yep because it's contingent on- That's how I netted out to $255-$260. Yeah. So yeah, I would agree with your comments. Very helpful, Glenn. Thanks very much for your time. Thank you. Appreciate it. Good seeing you.